Development and Implementation of a Coagulation Factor Testing Method Utilizing Autoverification in a High-volume Clinical Reference Laboratory Environment

J Pathol Inform. 2017 Jun 19:8:25. doi: 10.4103/jpi.jpi_95_16. eCollection 2017.

Abstract

Background: Testing coagulation factor activities requires that multiple dilutions be assayed and analyzed to produce a single result. The slope of the line created by plotting measured factor concentration against sample dilution is evaluated to discern the presence of inhibitors giving rise to nonparallelism. Moreover, samples producing results on initial dilution falling outside the analytic measurement range of the assay must be tested at additional dilutions to produce reportable results.

Methods: The complexity of this process has motivated a large clinical reference laboratory to develop advanced computer algorithms with automated reflex testing rules to complete coagulation factor analysis. A method was developed for autoverification of coagulation factor activity using expert rules developed with on an off the shelf commercially available data manager system integrated into an automated coagulation platform.

Results: Here, we present an approach allowing for the autoverification and reporting of factor activity results with greatly diminished technologist effort.

Conclusions: To the best of our knowledge, this is the first report of its kind providing a detailed procedure for implementation of autoverification expert rules as applied to coagulation factor activity testing. Advantages of this system include ease of training for new operators, minimization of technologist time spent, reduction of staff fatigue, minimization of unnecessary reflex tests, optimization of turnaround time, and assurance of the consistency of the testing and reporting process.

Keywords: Anticoagulants; autoverification; coagulation factor inhibitors; coagulation factors; coagulation testing; compliance; data management; expert rules; factor parallelism; hemostasis; laboratory automation; lupus anticoagulants; middleware; preanalytics; thrombosis.